header-logo header-logo

10 February 2017
Issue: 7733 / Categories: Case law , Law digest , In Court
printer mail-detail

Limitation of action

Lewin v Glaxo Operations UK Ltd (sued as Glaxosmithkline Unlimited) [2016] EWHC 3331 (QB), [2016] All ER (D) 122 (Dec)

The Queen’s Bench Division held that the claimant’s negligence proceedings against the defendant for personal injuries and consequential loss arising out of his exposure to Myodil in 1973 had been brought within the statutory limitation period. Although there could be no precision as to timing, the damage had probably been caused shortly before or in 2007 and the cause of action had arisen when the claimant had been diagnosed as suffering from post-Myodil adhesive arachnoiditis.

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

Hugh James—Jonathan Askin

Hugh James—Jonathan Askin

London corporate and commercial team announces partner appointment

Michelman Robinson—Daniel Burbeary

Michelman Robinson—Daniel Burbeary

Firm names partner as London office managing partner

Kingsley Napley—Jonathan Grimes

Kingsley Napley—Jonathan Grimes

Firm appoints new head of criminal litigation team

NEWS
Hugh James has secured 500 places on King’s College London’s new AI Literacy for Law course as part of a major firm-wide push to strengthen its responsible use of generative artificial intelligence
The criminal courts will sit to their maximum capacity next year, after the Lord Chancellor David Lammy lifted the cap on Crown Court sitting days
The Lord Chancellor David Lammy has set out his plans for ‘Blitz courts’, a national listing framework and other elements of the Leveson reforms
A former Commerzbank analyst has been sentenced to eight months in prison for lying during an employment tribunal hearing
The Information Commissioner’s Office (ICO) has joined with 60 data protection authorities from around the world to call for ‘urgent regulatory attention’ to the dangers of artificial intelligence (AI)
back-to-top-scroll